Gempharmatech Co. Ltd. A - Asset Resilience Ratio

Latest as of June 2025: 23.95%

Gempharmatech Co. Ltd. A (688046) has an Asset Resilience Ratio of 23.95% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See financial agility of Gempharmatech Co. Ltd. A to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

CN¥670.25 Million

≈ $98.08 Million USD Cash + Short-term Investments

Total Assets

CN¥2.80 Billion

≈ $409.51 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Gempharmatech Co. Ltd. A's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Gempharmatech Co. Ltd. A to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Gempharmatech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688046 stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥670.25 Million	23.95%
Total Liquid Assets	CN¥670.25 Million	23.95%

Asset Resilience Insights

Good Liquidity Position: Gempharmatech Co. Ltd. A maintains a healthy 23.95% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Gempharmatech Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Gempharmatech Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Wuhan Hvsen Biotechnology Co Ltd SHE:300871	Biotechnology	6.52%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%

Annual Asset Resilience Ratio for Gempharmatech Co. Ltd. A (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Gempharmatech Co. Ltd. A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	18.17%	CN¥467.34 Million ≈ $68.39 Million	CN¥2.57 Billion ≈ $376.46 Million	-6.58pp
2023-12-31	24.74%	CN¥637.72 Million ≈ $93.32 Million	CN¥2.58 Billion ≈ $377.18 Million	-10.37pp
2022-12-31	35.11%	CN¥791.24 Million ≈ $115.78 Million	CN¥2.25 Billion ≈ $329.79 Million	+15.59pp
2021-12-31	19.52%	CN¥205.80 Million ≈ $30.11 Million	CN¥1.05 Billion ≈ $154.29 Million	+12.58pp
2019-12-31	6.93%	CN¥26.92 Million ≈ $3.94 Million	CN¥388.14 Million ≈ $56.80 Million	--

pp = percentage points

About Gempharmatech Co. Ltd. A

SHG:688046 China Biotechnology

Market Cap

$1.15 Billion

CN¥7.84 Billion CNY

Market Cap Rank

#8470 Global

#2084 in China

Share Price

CN¥19.13

Change (1 day)

+7.53%

52-Week Range

CN¥12.57 - CN¥21.80

All Time High

CN¥34.14